|Bid||85.96 x 2200|
|Ask||86.05 x 1000|
|Day's Range||85.58 - 88.82|
|52 Week Range||72.05 - 92.64|
|Beta (5Y Monthly)||0.53|
|PE Ratio (TTM)||24.02|
|Earnings Date||Feb 04, 2020|
|Forward Dividend & Yield||2.44 (2.76%)|
|Ex-Dividend Date||Dec 12, 2019|
|1y Target Est||99.35|
DOW UPDATE Shares of Dow Inc. and Merck are retreating Friday afternoon, sending the Dow Jones Industrial Average into negative territory. The Dow (DJIA) was most recently trading 133 points lower (-0.
DOW UPDATE Dragged down by losses for shares of Dow Inc. and Merck, the Dow Jones Industrial Average is falling Friday afternoon. Shares of Dow Inc. (DOW) and Merck (MRK) are contributing to the blue-chip gauge's intraday decline, as the Dow (DJIA) was most recently trading 261 points, or 0.
DOW UPDATE Behind declines for shares of Dow Inc. and Walgreens Boots, the Dow Jones Industrial Average is declining Friday afternoon. The Dow (DJIA) was most recently trading 177 points (0.6%) lower, as shares of Dow Inc.
Koneksa Health, the leader in developing and implementing patient-focused digital biomarkers for drug development, along with Merck & Co, Inc. (NYSE: MRK) announced the publication of a peer-reviewed Phase I clinical trial evaluating the accuracy and sensitivity of mobile health (mHealth) technologies to measure heart rate and blood pressure.
DOW UPDATE Shares of Dow Inc. and Walgreens Boots are posting losses Friday morning, dragging the Dow Jones Industrial Average into negative territory. The Dow (DJIA) was most recently trading 104 points (0.
With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
DOW UPDATE Shares of Dow Inc. and Pfizer are seeing declines Friday morning, sending the Dow Jones Industrial Average into negative territory. The Dow (DJIA) was most recently trading 29 points (0.1%) lower, as shares of Dow Inc.
J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.
Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, Ibrance in the Biopharma segment are likely to have made up for lower sales in the Upjohn group.
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Many other members of Big Pharma spent more on dividends and stock buybacks, a strategy some view as shortsighted Continue reading...
DOW UPDATE Shares of Travelers and Nike are seeing declines Thursday afternoon, dragging the Dow Jones Industrial Average into negative territory. The Dow (DJIA) was most recently trading 16 points (0.
DOW UPDATE Shares of Travelers and Walt Disney are seeing declines Thursday afternoon, sending the Dow Jones Industrial Average into negative territory. Shares of Travelers (TRV) and Walt Disney (DIS) have contributed to the blue-chip gauge's intraday decline, as the Dow (DJIA) was most recently trading 90 points lower (-0.
BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.
While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q4 sales, generic competition for Lyrica is likely to have hurt the same.
Health Canada Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)
Virus originating in Wuhan, China affected stock markets Tuesday, but one analyst said reactions were too strong.
Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announced today that it will present at the “Frontiers in Academic Pathology” symposium, hosted by the Icahn School of Medicine at Mount Sinai, to be held on Friday, January 31, 2020 at The New York Academy of Medicine, 1216 Fifth Avenue in New York. The symposium focus will include molecular biomarkers, experimental diagnostics and liquid biopsies, all of which factor heavily in the development of BriaCell’s companion diagnostics under development, including BriaCell’s HLA-matching hypothesis and recently-announced Grade I/II biomarkers.
DOW UPDATE The Dow Jones Industrial Average is trading down Tuesday afternoon with shares of Boeing and Chevron seeing the biggest drops for the blue-chip average. Shares of Boeing (BA) and Chevron (CVX) are contributing to the index's intraday decline, as the Dow (DJIA) was most recently trading 166 points (0.